Rallybio Announces Reverse Merger with Avenzo Therapeutics
Struggling biotech firm Rallybio is pursuing a reverse merger with Avenzo Therapeutics after its previous deal with Candid Therapeutics fell through. The new entity, which will trade under the ticker AVZO on Nasdaq, has raised $215 million in financing and aims to close by year-end.
Topics: biotech capital raising merger